Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered computational target discovery, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management will engage in a fireside chat that will be accessible on-demand through Compugen's website starting September 5, 2025, at 7:00 AM ET. The presentation will remain available for 90 days on the company's Investor Relations section.
Compugen (NASDAQ: CGEN), società in fase clinica specializzata in immunoterapia oncologica e nella scoperta di target tramite AI/ML, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference. Il management terrà un fireside chat che sarà disponibile on-demand sul sito di Compugen a partire dal 5 settembre 2025 alle 7:00 ET. La presentazione resterà accessibile per 90 giorni nella sezione Investor Relations della società.
Compugen (NASDAQ: CGEN), una compañía en fase clínica dedicada a la inmunoterapia contra el cáncer y al descubrimiento de dianas mediante AI/ML, ha anunciado su participación en la H.C. Wainwright 27th Annual Global Investment Conference. La dirección ofrecerá un fireside chat que estará disponible on-demand en la web de Compugen desde el 5 de septiembre de 2025 a las 7:00 ET. La presentación quedará online durante 90 días en la sección de Investor Relations de la compañía.
Compugen (NASDAQ: CGEN), AI/ML 기반 계산적 표적 발굴을 전문으로 하는 임상 단계 암 면역치료 회사가 H.C. Wainwright 27th Annual Global Investment Conference에 참여한다고 발표했습니다. 경영진은 fireside chat에 참여하며 해당 영상은 2025년 9월 5일 오전 7:00 ET부터 Compugen 웹사이트에서 온디맨드로 제공됩니다. 발표 자료는 회사의 투자자 관계(Investor Relations) 섹션에 90일간 게재될 예정입니다.
Compugen (NASDAQ: CGEN), société en phase clinique spécialisée dans l'immunothérapie du cancer et la découverte de cibles par IA/ML, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference. La direction tiendra un fireside chat qui sera disponible à la demande sur le site de Compugen à partir du 5 septembre 2025 à 7h00 ET. La présentation restera accessible pendant 90 jours dans la rubrique Investor Relations de la société.
Compugen (NASDAQ: CGEN), ein in der klinischen Phase befindliches Unternehmen für Krebsimmuntherapie, das sich auf KI/ML-gestützte Zielidentifikation spezialisiert hat, kündigt seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference an. Das Management wird an einem Fireside-Chat teilnehmen, der ab dem 5. September 2025 um 7:00 Uhr ET on-demand auf der Compugen-Website abrufbar sein wird. Die Präsentation bleibt für 90 Tage im Investor-Relations-Bereich des Unternehmens verfügbar.
- None.
- None.
HOLON,
The fireside chat will be available on demand on the Investor Relations section of Compugen's website at www.cgen.com from Friday, September 5, 2025, 7:00 AM ET for 90 days.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302540915.html
SOURCE Compugen Ltd.
FAQ
When is Compugen's (CGEN) presentation at the H.C. Wainwright Conference?
How long will Compugen's (CGEN) H.C. Wainwright Conference presentation be available?
Where can I watch Compugen's (CGEN) H.C. Wainwright Conference presentation?
What type of company is Compugen (CGEN)?
